<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611153</url>
  </required_header>
  <id_info>
    <org_study_id>17-002907</org_study_id>
    <secondary_id>UL1TR000135</secondary_id>
    <nct_id>NCT03611153</nct_id>
  </id_info>
  <brief_title>MPO Inhibitor A_Zeneca for HFpEF</brief_title>
  <official_title>Hemodynamic Effects of a Novel Myeloperoxidase Inhibitor With Exercise in Heart Failure With Preserved Ejection Fraction - A Randomized, Double-Blind, Placebo Controlled Proof of Principle Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure
      versus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enroll subjects with a normal ejection fraction referred to the catheterization laboratory
      for evaluation of breathlessness or shortness of breath. Perform safety lab sampling,
      echocardiography, arterial tonometry for pulse wave analysis, and assessment of endothelial
      function prior to administration of study drug. During the catheterization researchers will
      perform blood draws, assess baseline exercise capacity at rest and during exercise.
      Researchers will also do an echocardiogram to take measurements of the heart. Subjects will
      be randomized to one of two groups, Oral Myeloperoxidase Inhibitor or placebo group. Study
      drug or placebo will be administered followed by a repeat of the baseline catheterization
      assessments. At the conclusion of the second exercise test the subject will be moved to a
      room and monitored overnight for safety. Repeat blood draws, echocardiogram, endothelial
      function test, and heart monitoring will be completed. The subject will be asked to follow up
      with the researchers between 9-14 days after the study drug dosage. The subjects history and
      blood work will be completed at that visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single Administration of study drug</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Only research pharmacy staff will be aware of randomization scheme and all study personnel and subjects will remain blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise Pulmonary capillary wedge pressure (PCWP)</measure>
    <time_frame>Baseline</time_frame>
    <description>Exercise PCWP values at 20 Watt workload. Measured in mmHg. Normal values are 4-12 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exercise Pulmonary capillary wedge pressure (PCWP)</measure>
    <time_frame>30min</time_frame>
    <description>Exercise PCWP values at 20 Watt workload. Measured in mmHg. Normal values are 4-12 mmHg</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Oral myeloperoxidase inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient may take 30 mg of oral myeloperoxidase inhibitor following baseline right heart catheterization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient may take 30 mg of placebo oral capsule following baseline right heart catheterization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Myeloperoxidase Inhibitor</intervention_name>
    <description>A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.</description>
    <arm_group_label>Oral myeloperoxidase inhibitor</arm_group_label>
    <other_name>Oral MPO inhibitor AZD4831</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females of non-childbearing potential

          2. Age ≥ 30 years

          3. Symptoms of dyspnea (II-IV) at the time of screening

          4. EF ≥ 50% as determined on imaging study within 12 months of enrollment

          5. Catheterization documented elevated filling pressures at rest (PCWP ≥15) or with
             exercise (PCWP ≥25)

        Exclusion Criteria:

          1. Use of nitrates, phosphodiesterase 5 inhibitors or other NO-providing therapy in the
             past 24 hours of screening

          2. Significant valvular disease (&gt;moderate left-sided regurgitation, &gt;mild stenosis)

          3. Requirement of intravenous heparin at the start of case

          4. Severe pulmonary parenchymal disease

          5. Acute coronary syndrome or coronary disease requiring revascularization in the
             judgement of investigators

          6. Resting systolic blood pressure &lt; 100 mmHg

          7. Constrictive pericarditis

          8. Infiltrative, restrictive, or hypertrophic obstructive cardiomyopathies

          9. Previous anaphylaxis to any drug

         10. Pregnancy or breastfeeding mothers

         11. High Output heart failure

         12. Active thyroid disease

         13. Treatment with a new chemical entity (defined as a compound which has not been
             approved for marketing) within the preceding 3 months

         14. Patients with any prior allergy to propylthiouracil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry A Borlaug, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole M Knutson</last_name>
    <phone>507-255-2200</phone>
    <email>Knutson.Nicole1@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole M Knutson</last_name>
      <phone>507-255-2200</phone>
      <email>Knutson.Nicole1@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Barry Borlaug</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Ejection Fraction</keyword>
  <keyword>Preserved</keyword>
  <keyword>Myeloperoxidase Inhibitor</keyword>
  <keyword>Exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

